Literature DB >> 6433985

Lysophosphatidic acid can activate platelets without increasing 32P-labelling of phosphatidic acid.

J M Gerrard, P Robinson.   

Abstract

Stimulation of platelets by thrombin produced a rise in [32P]phosphatidic acid labelling of platelets which was greater in medium without added calcium than in medium with 2.5 mM calcium. A rise in [32P]lysophosphatidic acid was also seen in platelets stimulated by thrombin in the presence of 2.5 mM extracellular calcium, though it was of lesser magnitude (average 35%) than the rise in phosphatidic acid. In platelets resuspended without added calcium no change in [32P]lysophosphatidic acid was seen in response to thrombin. Lysophosphatidic acid can itself induce platelet aggregation. Similarly to the calcium ionophore A23187, lysophosphatidic acid produced minimal change (in medium with no added calcium) to no change (in medium with 2.5 mM external calcium) in [32P]lysophosphatidic acid. The endoperoxide analog U46619 produced changes in 32P-labelling of platelet phosphatidic and lysophosphatidic acid similar to those produced by thrombin but of lesser magnitude. The results of these studies show that the action of lysophosphatidic acid on platelets differs from the action of thrombin, U46619 and platelet-activating factor, which produce a rapid rise in [32P]phosphatidic acid, and suggests that lysophosphatidic acid, like A23187, largely bypasses the initial receptor-coupled breakdown of phosphoinositides leading to formation of diacylglycerols and phosphatidic acid.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433985     DOI: 10.1016/0005-2760(84)90177-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions.

Authors:  W Siess; K J Zangl; M Essler; M Bauer; R Brandl; C Corrinth; R Bittman; G Tigyi; M Aepfelbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  Increased formation of phosphatidylinositol-4-phosphate in human platelets stimulated with lysophosphatidic acid.

Authors:  I Mani; D C Gaudette; B J Holub
Journal:  Lipids       Date:  1996-12       Impact factor: 1.880

3.  The bioactive phospholipid lysophosphatidic acid is released from activated platelets.

Authors:  T Eichholtz; K Jalink; I Fahrenfort; W H Moolenaar
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

Review 4.  Therapeutic potential of autotaxin/lysophospholipase d inhibitors.

Authors:  Lorenzo Federico; Zehra Pamuklar; Susan S Smyth; Andrew J Morris
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

Review 5.  Roles of lysophosphatidic acid in cardiovascular physiology and disease.

Authors:  Susan S Smyth; Hsin-Yuan Cheng; Sumitra Miriyala; Manikandan Panchatcharam; Andrew J Morris
Journal:  Biochim Biophys Acta       Date:  2008-06-10

6.  Lysophosphatidic acid induced nuclear translocation of nuclear factor-kappaB in Panc-1 cells by mobilizing cytosolic free calcium.

Authors:  Yoshiyuki Arita; Tetsuhide Ito; Takamasa Oono; Ken Kawabe; Terumasa Hisano; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

7.  Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action. Evidence against a second messenger role for lysophosphatidic acid.

Authors:  S P Watson; R T McConnell; E G Lapetina
Journal:  Biochem J       Date:  1985-11-15       Impact factor: 3.857

8.  Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.

Authors:  Zehra Pamuklar; Lorenzo Federico; Shuying Liu; Makiko Umezu-Goto; Anping Dong; Manikandan Panchatcharam; Zachary Fulkerson; Zachary Fulerson; Evgeny Berdyshev; Viswanathan Natarajan; Xianjun Fang; Laurens A van Meeteren; Wouter H Moolenaar; Gordon B Mills; Andrew J Morris; Susan S Smyth
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.